Ipsos Healthcare Expands Syndicated Monitors to China

Ipsos Healthcare has extended its syndicated Psoriasis and IBD Therapy Monitors into China, where it will also re-launch its Lupus Therapy Monitor.

The new Chinese autoimmune studies, part of Ipsos' syndicated Global Therapy Monitor portfolio, will incorporate real patient record data with doctors' perceptions to analyse the current market landscape, market shares, reasons behind treatment trends and potential impact of products in development. The studies aim to complement the division's existing real world evidence offer in China, which spans oncology, diabetes, cardiovascular, respiratory and virology diseases.

Paul O'Meara (pictured), SVP of Autoimmune Therapy Monitors, comments: 'It is a very exciting time in the autoimmune arena, with a wide variety of new targeted biologic treatments and biosimilars offering greater treatment options for patients. We are delighted to expand our Psoriasis, IBD and Lupus studies into China to meet the global and local research needs of our clients'.

Web site: www.ipsoshealthcare.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.